NasdaqGS:GTHX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has G1 Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GTHX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-20.3%

GTHX

-0.8%

US Biotechs

-1.9%

US Market


1 Year Return

-63.0%

GTHX

33.5%

US Biotechs

13.1%

US Market

Return vs Industry: GTHX underperformed the US Biotechs industry which returned 33.5% over the past year.

Return vs Market: GTHX underperformed the US Market which returned 13.1% over the past year.


Shareholder returns

GTHXIndustryMarket
7 Day-20.3%-0.8%-1.9%
30 Day-20.2%1.6%-2.9%
90 Day-48.0%-3.2%8.2%
1 Year-63.0%-63.0%35.8%33.5%15.7%13.1%
3 Year-50.7%-50.7%18.0%12.3%38.4%29.1%
5 Yearn/a23.7%14.9%89.3%68.0%

Price Volatility Vs. Market

How volatile is G1 Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is G1 Therapeutics undervalued compared to its fair value and its price relative to the market?

2.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GTHX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GTHX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GTHX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: GTHX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GTHX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GTHX is good value based on its PB Ratio (2.3x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is G1 Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-3.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GTHX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GTHX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GTHX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GTHX's revenue (57% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: GTHX's revenue (57% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GTHX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has G1 Therapeutics performed over the past 5 years?

-32.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GTHX is currently unprofitable.

Growing Profit Margin: GTHX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GTHX is unprofitable, and losses have increased over the past 5 years at a rate of 32.5% per year.

Accelerating Growth: Unable to compare GTHX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GTHX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: GTHX has a negative Return on Equity (-63.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is G1 Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: GTHX's short term assets ($240.1M) exceed its short term liabilities ($21.9M).

Long Term Liabilities: GTHX's short term assets ($240.1M) exceed its long term liabilities ($27.8M).


Debt to Equity History and Analysis

Debt Level: GTHX's debt to equity ratio (9.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if GTHX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GTHX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: GTHX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 34.2% each year.


Next Steps

Dividend

What is G1 Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GTHX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GTHX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GTHX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GTHX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GTHX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Mark Velleca (56 yo)

6.33yrs

Tenure

US$3,983,445

Compensation

Dr. Mark A. Velleca, M.D., Ph.D., has been Chief Executive Officer of G1 Therapeutics, Inc. since May 20, 2014 and has been its President since May 2014. Dr. Velleca served as Senior Advisor at Gilead Scie ...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD3.98M) is above average for companies of similar size in the US market ($USD2.02M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Mark Velleca
CEO, President & Director6.33yrsUS$3.98m0.097%
$ 461.0k
Jennifer Moses
Chief Financial Officer1.33yrsUS$1.41m0.029%
$ 137.1k
Rajesh Malik
Chief Medical Officer and Senior VP of R&D6.17yrsUS$1.39m0.077%
$ 363.8k
Mark Avagliano
Chief Business Officer1.17yrsUS$5.66mno data
Terry Murdock
Chief Operating Officer1.67yrsUS$2.75m0%
$ 0
Alexander Smith
Vice President of Technical Operations5.42yrsno datano data
Jay Strum
Chief Scientific Officer11.67yrsno data0.34%
$ 1.6m
Jeff Macdonald
Senior Director of Investor Relations & Corporate Communications2.67yrsno datano data
Blake Jensen
Vice President of Quality & Compliance2.67yrsno datano data
James Hanson
General Counsel & Corporate Secretary2.25yrsUS$5.06m0.011%
$ 49.8k
JoAnne Zellner
Head of Human Resources2.67yrsno datano data
David Elks
Head of Information Technology2.17yrsno datano data

2.7yrs

Average Tenure

56yo

Average Age

Experienced Management: GTHX's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Velleca
CEO, President & Director6.33yrsUS$3.98m0.097%
$ 461.0k
Seth Rudnick
Independent Director & Member of Clinical Advisory Boardno dataUS$325.52k0.15%
$ 726.2k
Glenn Muir
Independent Director5yrsUS$317.61k0.47%
$ 2.2m
Joseph Bailes
Scientific & Clinical Advisorno datano datano data
Fredric Eshelman
Independent Director5.58yrsUS$296.67k0.66%
$ 3.1m
George Demetri
Scientific & Clinical Advisorno datano datano data
Cynthia Schwalm
Independent Director2.25yrsUS$307.37k0.0040%
$ 18.7k
Garry Nicholson
Independent Chairman of the Board1.25yrsUS$1.51m0%
$ 0
Gary Lyman
Scientific & Clinical Advisorno datano datano data
Kwok-Kin Wong
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Donald McDonnell
Scientific & Clinical Advisorno datano datano data
Geoffrey Shapiro
Scientific & Clinical Advisorno datano datano data

5.0yrs

Average Tenure

63yo

Average Age

Experienced Board: GTHX's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: GTHX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

G1 Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: G1 Therapeutics, Inc.
  • Ticker: GTHX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$473.662m
  • Shares outstanding: 38.01m
  • Website: https://www.g1therapeutics.com

Number of Employees


Location

  • G1 Therapeutics, Inc.
  • 700 Park Offices Drive
  • Suite 200
  • Research Triangle Park
  • North Carolina
  • 27709
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GTHXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2017
G1HDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2017

Biography

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/24 05:53
End of Day Share Price2020/09/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.